-
公开(公告)号:US20120053179A1
公开(公告)日:2012-03-01
申请号:US13289782
申请日:2011-11-04
申请人: Dhanapalan Nagarathnam , Jacques Dumas , Holia Hatoum-Mokdad , Stephen Boyer , Chunguang Wang , Hans Pluempe , Achim Feurer , Samir Bennabi
发明人: Dhanapalan Nagarathnam , Jacques Dumas , Holia Hatoum-Mokdad , Stephen Boyer , Chunguang Wang , Hans Pluempe , Achim Feurer , Samir Bennabi
IPC分类号: A61K31/5377 , C07D401/14 , C07D471/04 , C07D401/12 , C07D405/14 , C07D409/14 , C07D413/14 , A61K31/505 , A61K31/506 , A61K31/517 , A61K31/519 , A61P9/12 , A61P9/10 , A61P25/00 , A61P25/28 , A61P35/00 , A61P7/02 , A61P11/06 , A61P27/06 , A61P19/10 , A61P15/00 , C07D239/48
CPC分类号: C07D239/48 , A61K31/506 , C07D401/12 , C07D403/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D471/04
摘要: Disclosed are compounds and derivatives thereof, their synthesis, and their use as Rho-kinase inhibitors. These compounds are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease.
摘要翻译: 公开了其化合物及其衍生物,其合成及其作为Rho-激酶抑制剂的用途。 这些化合物可用于抑制肿瘤生长,治疗勃起功能障碍和治疗由Rho-激酶介导的其它适应症,例如冠心病。
-
公开(公告)号:US20050209261A1
公开(公告)日:2005-09-22
申请号:US11111704
申请日:2005-04-22
IPC分类号: C07D239/48 , A61K31/505 , A61K31/506 , A61K31/517 , A61P7/02 , A61P9/00 , A61P9/10 , A61P9/12 , A61P11/06 , A61P15/10 , A61P19/10 , A61P25/00 , A61P25/06 , A61P25/28 , A61P27/06 , A61P35/00 , A61P43/00 , C07D401/12 , C07D401/14 , C07D43/14
CPC分类号: C07D401/12 , C07D401/14
摘要: Disclosed are compounds and derivatives thereof, their synthesis, and their use as Rho-kinase inhibitors. These compounds are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease.
-
13.INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS 审中-公开
标题翻译: 使用对称和非对称二苯醚类尿素抑制P38激酶公开(公告)号:US20090093526A1
公开(公告)日:2009-04-09
申请号:US11932397
申请日:2007-10-31
申请人: Scott Miller , Martin Osterhout , Jacques Dumas , Uday Khire , Timothy B. Lowinger , William J. Scott , Roger A. Smith , Jill E. Wood , David E. Gunn , Holia Hatoum-Mokdad , Marell Rodriguez , Robert Sibley , Ming Wang , Tiffany Turner , Catherine Brennan
发明人: Scott Miller , Martin Osterhout , Jacques Dumas , Uday Khire , Timothy B. Lowinger , William J. Scott , Roger A. Smith , Jill E. Wood , David E. Gunn , Holia Hatoum-Mokdad , Marell Rodriguez , Robert Sibley , Ming Wang , Tiffany Turner , Catherine Brennan
IPC分类号: A61K31/40 , A61K31/44 , C07D207/36 , C07D213/04 , A61P19/02
CPC分类号: A61K31/17 , A61K31/341 , A61K31/381 , A61K31/4035 , A61K31/44 , A61K31/5375 , Y02A50/411
摘要: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.
摘要翻译: 本发明涉及一组芳基脲在治疗细胞因子介导的疾病和蛋白水解酶介导的疾病中的用途,以及用于这种治疗的药物组合物。
-
14.OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS 有权
标题翻译: 作为RAF激酶抑制剂的OMEGA-CARBOXYARYL替代二苯醚公开(公告)号:US20120142742A1
公开(公告)日:2012-06-07
申请号:US13368812
申请日:2012-02-08
申请人: Bernd Riedl , Jacques Dumas , Uday Khire , Timothy B. Lowinger , William J. Scott , Roger A. Smith , Jill E. Wood
发明人: Bernd Riedl , Jacques Dumas , Uday Khire , Timothy B. Lowinger , William J. Scott , Roger A. Smith , Jill E. Wood
CPC分类号: C07C275/36 , C07C275/28 , C07C275/30 , C07C275/32 , C07C275/40 , C07C311/29 , C07C317/22 , C07D209/46 , C07D209/48 , C07D213/75 , C07D213/81 , C07D213/82 , C07D295/13 , C07D295/135 , C07D295/192 , C07D413/12
摘要: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
摘要翻译: 本发明涉及一组芳基脲在治疗raf介导的疾病中的用途,以及用于此类治疗的药物组合物。
-
15.Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas 审中-公开
标题翻译: 使用芳基和杂芳基取代的杂环脲抑制p38激酶活性公开(公告)号:US20080300281A1
公开(公告)日:2008-12-04
申请号:US12181032
申请日:2008-07-28
申请人: Jacques Dumas , Uday Khire , Timothy B. Lowinger , Bernd Riedl , William J. Scott , Roger A. Smith , Jill E. Wood , Holia Hatoum-Mokdad , Jeffrey Johnson , Aniko Redman , Robert Sibley
发明人: Jacques Dumas , Uday Khire , Timothy B. Lowinger , Bernd Riedl , William J. Scott , Roger A. Smith , Jill E. Wood , Holia Hatoum-Mokdad , Jeffrey Johnson , Aniko Redman , Robert Sibley
IPC分类号: A61K31/4439 , A61K31/415 , A61K31/4427 , A61K31/381 , A61P19/02
CPC分类号: A61K31/381 , A61K31/415 , A61K31/4427 , A61K31/4439 , Y02A50/411
摘要: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases other than cancer and proteolytic enzyme mediated diseases other than cancer, and pharmaceutical compositions for use in such therapy.
摘要翻译: 本发明涉及一组芳基脲在治疗癌症以外的细胞因子介导的疾病和除了癌症以外的蛋白水解酶介导的疾病以及用于这种治疗的药物组合物中的用途。
-
16.
公开(公告)号:US20080293696A1
公开(公告)日:2008-11-27
申请号:US11630850
申请日:2005-06-23
申请人: Catherine Brennan , Julie A. Dixon , William J. Scott , Aniko Redman , Benjamin D. Jones , Barton Phillips , Philip Wickens , Istvan Enyedy , Ellalahewage Kumarasinghe , Charles Kreiman , Jacques Dumas , Uday Khire , Chih-Yuan Chuang , Harold C.E. Kluender , Zhenqiu Hong , Lei Wang , Donald Bierer
发明人: Catherine Brennan , Julie A. Dixon , William J. Scott , Aniko Redman , Benjamin D. Jones , Barton Phillips , Philip Wickens , Istvan Enyedy , Ellalahewage Kumarasinghe , Charles Kreiman , Jacques Dumas , Uday Khire , Chih-Yuan Chuang , Harold C.E. Kluender , Zhenqiu Hong , Lei Wang , Donald Bierer
IPC分类号: A61K31/55 , C07D405/12 , A61K31/4433 , A61K31/444 , A61P35/00 , C07D405/14 , A61K31/506
CPC分类号: C07D319/08
摘要: A compound having the formula (1) in which the ring containing E is a phenyl, a pyridine, or a pyrimidine. In formula (1) the symbol A represents wherein the group R4 represents halogen, CF3, or H, provided that the maximum number of CF3 groups on any A is 2, and the maximum number of hydrogens on A is 2 for the A groups which together with the carbon atoms to which they are attached form 6-membered rings, and the maximum number of hydrogens on A is 1 for the A group which together with the carbon atoms to which it is attached forms a 5-membered ring. Z represents N or CH when E forms a phenyl ring, and represents CH when E forms a pyridine or pyrimidine. The groups R1, R2 and R3 and the subscripts a, b, and d are as defined in the text and claims. Pharmaceutical compositions containing a compound of formula (1) and methods of treating cancer using compounds of formula (1) are also disclosed and claimed.
摘要翻译: 具有式(1)的化合物,其中含有E的环是苯基,吡啶或嘧啶。 在式(1)中,符号A表示其中基团R 4表示卤素,CF 3或H,条件是任何A上的CF 3基团的最大数目为2,并且A组中的最大氢数为2, 与它们连接的碳原子一起形成6元环,并且对于与连接的碳原子一起形成5元环的A基团,A上的最大氢数为1。 当E形成苯环时,Z表示N或CH,当E形成吡啶或嘧啶时,Z表示CH。 基团R1,R2和R3以及下标a,b和d如本文和权利要求中所定义。 还公开并要求保护含有式(1)化合物的药物组合物和使用式(1)化合物治疗癌症的方法。
-
17.Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors 有权
标题翻译: ω-羧基芳基取代的二苯脲作为raf激酶抑制剂公开(公告)号:US08841330B2
公开(公告)日:2014-09-23
申请号:US13368812
申请日:2012-02-08
申请人: Bernd Riedl , Jacques Dumas , Uday Khire , Timothy B. Lowinger , William J. Scott , Roger A. Smith , Jill E. Wood
发明人: Bernd Riedl , Jacques Dumas , Uday Khire , Timothy B. Lowinger , William J. Scott , Roger A. Smith , Jill E. Wood
IPC分类号: A61K31/44
CPC分类号: C07C275/36 , C07C275/28 , C07C275/30 , C07C275/32 , C07C275/40 , C07C311/29 , C07C317/22 , C07D209/46 , C07D209/48 , C07D213/75 , C07D213/81 , C07D213/82 , C07D295/13 , C07D295/135 , C07D295/192 , C07D413/12
摘要: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
摘要翻译: 本发明涉及一组芳基脲在治疗raf介导的疾病中的用途,以及用于此类治疗的药物组合物。
-
18.Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors 有权
标题翻译: ω-羧基芳基取代的二苯脲作为raf激酶抑制剂公开(公告)号:US07235576B1
公开(公告)日:2007-06-26
申请号:US10042203
申请日:2002-01-11
申请人: Bernd Riedl , Jacques Dumas , Uday Khire , Timothy B. Lowinger , William J. Scott , Roger A. Smith , Jill E. Wood , Mary-Katherine Monahan , Reina Natero , Joel Renick , Robert N. Sibley
发明人: Bernd Riedl , Jacques Dumas , Uday Khire , Timothy B. Lowinger , William J. Scott , Roger A. Smith , Jill E. Wood , Mary-Katherine Monahan , Reina Natero , Joel Renick , Robert N. Sibley
IPC分类号: A61K31/17 , A61K31/44 , C07D213/30 , C07C275/18 , C07C275/34
CPC分类号: C07D209/48 , C07D213/75 , C07D213/81 , C07D401/12
摘要: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
摘要翻译: 本发明涉及一组芳基脲在治疗raf介导的疾病中的用途,以及用于此类治疗的药物组合物。
-
19.2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists 审中-公开
标题翻译: 用作β-3肾上腺素受体激动剂的2,6-取代的苯并二氢吡喃衍生物公开(公告)号:US20050215594A1
公开(公告)日:2005-09-29
申请号:US11117759
申请日:2005-04-28
申请人: Stephen O'Connor , Gaetan Ladouceur , William Bullock , Ann-Marie Campbell , Miao Dai , Robert Dally , Jacques Dumas , Holia Hatoum-Mokdad , Uday Khire , Wendy Lee , Qingjie Liu , Derek Lowe , Steven Magnuson , Ning Qi , Tatiana Skelekhin , Quanrong Shen , Roger Smith , Ming Wang
发明人: Stephen O'Connor , Gaetan Ladouceur , William Bullock , Ann-Marie Campbell , Miao Dai , Robert Dally , Jacques Dumas , Holia Hatoum-Mokdad , Uday Khire , Wendy Lee , Qingjie Liu , Derek Lowe , Steven Magnuson , Ning Qi , Tatiana Skelekhin , Quanrong Shen , Roger Smith , Ming Wang
IPC分类号: A61K31/353 , A61K31/357 , A61K31/4433 , A61K31/4436 , A61K31/4439 , A61K31/506 , A61K31/69 , A61P1/04 , A61P3/04 , A61P3/06 , A61P3/10 , A61P5/48 , A61P9/10 , A61P13/12 , C07D311/58 , C07D405/12 , C07D405/14 , C07D407/04 , C07D407/12 , C07D407/14 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/14 , C07D45/02
CPC分类号: C07D405/12 , C07D311/58 , C07D405/14 , C07D407/12 , C07D409/12 , C07D413/12 , C07D417/14
摘要: This invention relates to novel 2,6-substituted chroman derivatives which are useful in the treatment of beta-3 adrenoreceptor-mediated conditions.
摘要翻译: 本发明涉及可用于治疗β-3肾上腺素受体介导的病症的新的2,6-取代的苯并二氢吡喃衍生物。
-
20.2,6-substituted chroman derivatives useful as beta-3 adrenoreceptor agonists 失效
标题翻译: 用作β-3肾上腺素受体激动剂的2,6-取代的苯并二氢吡喃衍生物公开(公告)号:US06919371B2
公开(公告)日:2005-07-19
申请号:US10666903
申请日:2003-09-17
申请人: Stephen J. O'Connor , Gaetan H. Ladouceur , William H. Bullock , Ann-Marie Campbell , Miao Dai , Robert Dally , Jacques Dumas , Holia N. Hatoum-Mokdad , Uday Khire , Wendy Lee , Qingjie Liu , Derek B. Lowe , Steven R. Magnuson , Ning Qi , Tatiana E. Shelekhin , Quanrong Shen , Roger A. Smith , Ming Wang
发明人: Stephen J. O'Connor , Gaetan H. Ladouceur , William H. Bullock , Ann-Marie Campbell , Miao Dai , Robert Dally , Jacques Dumas , Holia N. Hatoum-Mokdad , Uday Khire , Wendy Lee , Qingjie Liu , Derek B. Lowe , Steven R. Magnuson , Ning Qi , Tatiana E. Shelekhin , Quanrong Shen , Roger A. Smith , Ming Wang
IPC分类号: A61K31/353 , A61K31/357 , A61K31/4433 , A61K31/4436 , A61K31/4439 , A61K31/506 , A61K31/69 , A61P1/04 , A61P3/04 , A61P3/06 , A61P3/10 , A61P5/48 , A61P9/10 , A61P13/12 , C07D311/58 , C07D405/12 , C07D405/14 , C07D407/04 , C07D407/12 , C07D407/14 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/14 , A61K31/352
CPC分类号: C07D405/12 , C07D311/58 , C07D405/14 , C07D407/12 , C07D409/12 , C07D413/12 , C07D417/14
摘要: This invention relates to novel 2,6-substituted chroman derivatives which are useful in the treatment of beta-3 adrenoreceptor-mediated conditions.
摘要翻译: 本发明涉及可用于治疗β-3肾上腺素受体介导的病症的新的2,6-取代的苯并二氢吡喃衍生物。
-
-
-
-
-
-
-
-
-